Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astegolimab - Genentech

Drug Profile

Astegolimab - Genentech

Alternative Names: AMG-282; Anti-ST2; MSTT 1041 A; RG 6149; RO 7187807; ST2 MAb

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech; Roche; University of Leicester
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Atopic dermatitis
  • Discontinued Asthma; COVID-19 pneumonia; Rhinosinusitis

Most Recent Events

  • 17 Jun 2024 Genentech initiates enrolment in a phase I trial (In volunteers) in USA (NCT06462118)
  • 09 May 2024 Roche plans to submit regulatory fillings in Chronic obstructive pulmonary disease, in 2025 (Roche pipeline, May 2024)
  • 09 Sep 2023 Updated efficacy data from a phase II trial in Chronic obstructive pulmonary disease presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top